ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will ...
Pharmaceutical Technology13h
Leveragen and Moonlight Bio unite for T-cell therapy development
Leveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for ...
BioPharma Dive18h
Enhertu, with new OK, set to supplant chemo in HER2-low breast cancer
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
PharmiWeb1d
Antibody Therapy Market to Surge, Expected to Reach USD 824 Billion by 2033 at a 13.4% of CAGR
Antibody Therapy MarketThe global antibody therapy market is on a strong growth trajectory, projected to expand at a CAGR of ...
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.DN-d7ZPu.js ...
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258
OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...
IMAC Holdings, Inc.: IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies
IMAC Holdings, Inc. (Nasdaq: BACK) ("IMAC Holdings" or the "Company") has launched Ignite Proteomics LLC ("Ignite"), its new subsidiary dedicated to helping ...
The American Journal of Managed Care2d
Emerging Therapies Shine Hope on Small Cell Lung Cancer Treatment
Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...
The American Journal of Managed Care2d
FDA Approves Trastuzumab Deruxtecan for HER2-Low/Ultralow Breast Cancer
The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.
PharmiWeb2d
Enhertu approved in the US as first HER2-directed…
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...
Technology is enabling more precise treatments for cancer patients
The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side ...
AstraZeneca, Daiichi’s drug cleared for wider use in breast cancer patients in US
Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the ...